Priority,Rule
Very High,"1. GSK-sponsored pivotal trials (usually ph 3, 2), pivotal key competitor studies that may change the SoC, ground-breaking data, high-quality ISS from key competitors or other competitors of interest that may change the SoC (GSK or competitor sponsored, well-known academic center, multiple academic centers, consortiums, key indication/s of interest) ​
2. GSK- or key competitor–sponsored symposia in indication/s of interest ​

Session type considerations ​not rules
 * Only Oral presentations will be considered 
* Secondary condition: LBA/Oral presentation that will be part of a presidential or highlighted as a news of the day, by the congress​

"
High,"1. Company-sponsored pivotal trials (usually ph 3, 2) from other competitors of interest​
2. High-quality RWE/HEOR studies from key competitors or competitors that may change the SoC (large database, indication of interest, potential to change SoC, or inform a study that can change SoC) ​
3. ISS from key competitors or other competitors of interest [well-known academic center, indication of interest, multiple academic centers (>20), consortiums] ​
4. GSK- or key competitor–sponsored medical education sessions on indications of interest (including IME where available)​
5. Any pivotal/ground-breaking company-sponsored ph 1 datasets from key competitors (assets that have not had a pivotal data readout or assets going into rare indications)​

Session type considerations ​not Rules:
* Oral presentations​
* Poster/e-poster presentations to be considered only when it fulfils any of the above criteria    "
Internal​,"GSK-sponsored relevant abstracts (with indication of interest and keywords) excluding GSK-sponsored pivotal trials (usually ph 3, 2), pivotal key competitor studies that may change the SoC or GSK sponsored symposia or medical education session - as they are considered as Very High/High"
Medium,"1. Non-pivotal studies from key competitors ​
2. Single-center, single-country datasets from key competitors and other emerging competitors of interest​
3. Any abstract with clinical data which do not fall under Very High/High criteria​

Session type considerations ​not rules
* Oral presentations​
* Poster or e-poster presentations​

Trials in progress (TIP)"
Low,Non-clinical/pre-clinical studies from key competitors or other competitors of interest 
